Bymetric
UK company intelligence
Company Active LTD

Company profile

Cytox Limited

Home - genoSCORE-LAB

Cytox Limited is a UK company with status active founded in 2004.

CRN
05149130
Founded
2004
Age
22

Overview

Legal name
CYTOX LIMITED
Region
Unknown
Registered address
2ND FLOOR ABBEY HOUSE
32 BOOTH STREET
MANCHESTER
M2 4AB
Insolvency history
Yes

Company events

Reference milestones and recent Companies House filing stream events.

5 events
23 Jun
2024

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2023

Accounts due

Accounts Due

Next accounts due date

09 Jun
2023

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2021

Accounts filed

Accounts

Last accounts made up date

09 Jun
2004

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2015
Funded years
2015, 2018, 2020
Age at first award
10 years

Projects

2020 Feasibility Studies Lead participant

Completion of software development and product launch activities associated with commercialisation of current Innovate UK Project (5195)

1 Jun 2020 to 30 Nov 2020

Awarded
£215,491
Total cost £215,491

no public description

2018 Collaborative R&D Lead participant

The development and implementation of polygenic risk scoring algorithms for stratifying individuals for future cognitive decline due to Alzheimer's Disease in non-symptomatic and early cognitive impaired subjects

1 Mar 2018 to 31 Dec 2020

Awarded
£573,966
Total cost £819,952

This project will evaluate the utility of genetic based risk stratification for future cognitive decline in cognitively normal subjects and those with Mild Cognitive Impairment (MCI). MCI may be a prodromal state for AD (Alzheimer's Disease) and 50-60% of these patients are at high risk of progression to AD, however current prognostic methods for AD are o...

2015 Collaborative R&D Lead participant

The utility of mTOR signalling pathway dysregulation and mutational profiling in the risk stratification for future cognitive decline in Mild Cognitive Impairment (MCI).

1 Apr 2015 to 31 Mar 2018

Awarded
£720,620
Total cost £1,201,033

This project will evaluate the clinical utility of mTOR signalling pathway dysregulation and DNA sequence profiling in the risk stratification for future cognitive decline in Mild Cognitive Impairment (MCI). Dysregulation of the mTOR pathway has been identified as a risk factor in the development of AD. This project will confirm that proprietary biomarker...

Product types

Collaborative R&D Feasibility Studies